Categories: HealthcareNews

Avantor® to Host Second Quarter 2024 Earnings Call on Friday, July 26, 2024

RADNOR, Pa., June 28, 2024 /PRNewswire/ — Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its second quarter 2024 financial results before the market opens on Friday, July 26, and will hold a conference call on the same day at 8:00 a.m. Eastern Time to discuss the results.

To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor’s website, ir.avantorsciences.com. A replay of the webcast will be available for 30 days.

About Avantor
Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedInX (Twitter) and Facebook.

Global Media Contact
Emily Collins
Vice President, External Communications
Avantor
332-239-3910
Emily.Collins@avantorsciences.com

Investor Relations Contact
Christina Jones
Vice President, Investor Relations
Avantor
805-617-5297
Christina.Jones@avantorsciences.com

View original content:https://www.prnewswire.com/news-releases/avantor-to-host-second-quarter-2024-earnings-call-on-friday-july-26-2024-302185117.html

SOURCE Avantor and Financial News

Staff

Recent Posts

Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics

GENEVA, SWITZERLAND / ACCESS Newswire / December 15, 2025 / MindMaze Therapeutics Holding SA (SIX:MMTX)…

58 minutes ago

Vaxxas Secures TGA Licence to Manufacture Therapeutic Goods

Milestone enables GMP manufacturing to accelerate clinical trials and transform global vaccine delivery BRISBANE, Australia…

19 hours ago

InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial

BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading…

19 hours ago

President Trump’s Cannabis Decision Is Coming – And Why MMJ International Holdings Wins Either Way

12 Month Timeline - How Cannabis Rescheduling Actually Takes EffectAnnouncementPresident signals intent or issues executive…

2 days ago

Accelerating Patient Recruitment and Research Excellence: TrialWire® Supports Endpoints Clinical Trials Day NYC 2025

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- TrialWire®, the industry’s fastest, intelligent patient recruitment…

2 days ago